BACIGUENT Drug Patent Profile
✉ Email this page to a colleague
When do Baciguent patents expire, and when can generic versions of Baciguent launch?
Baciguent is a drug marketed by Pharmacia And Upjohn and is included in one NDA.
The generic ingredient in BACIGUENT is bacitracin. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bacitracin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Baciguent
A generic version of BACIGUENT was approved as bacitracin by PADAGIS US on December 31st, 1969.
Summary for BACIGUENT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 24 |
Clinical Trials: | 1 |
Patent Applications: | 3,191 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BACIGUENT at DailyMed |
Recent Clinical Trials for BACIGUENT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Susan Hassenbein | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for BACIGUENT
US Patents and Regulatory Information for BACIGUENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacia And Upjohn | BACIGUENT | bacitracin | OINTMENT;OPHTHALMIC | 060734-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |